Gamunex-C is indicated for the treatment of:
- Primary humoral immunodeficiency disease (PIDD) in patients two years of age and older.
- Idiopathic thrombocytopenic purpura (ITP) in adults and children.
- Chronic inflammatory demyelinating polyneuropathy (CIDP) in adults.
Gamunex-C is:
- First and only USFDA approved for CIDP.
- Approved to be infused with higher infusion rates (Up to 0.08 ml/kg/min).
- Approved to be given over 2 days rather than 5 days.
